MTNB (Matinas BioPharma Holdings) GF Score: 31/100 (As of Jul. 03, 2026) — 14% Below Median


MTNB Matinas BioPharma Holdings Inc MTNB
31 GF Score
Price $0.63
! 3 Warning Signs
View Full Analysis

What is Matinas BioPharma Holdings GF Score?

Matinas BioPharma Holdings MTNB +0.43% 31 GF Score is 31 as of Jul. 03, 2026, which is 14% below its 10-year median of 36.00. GuruFocus rates MTNB with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Matinas BioPharma Holdings has the GF Score of 31, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 2/10
5. Momentum Rank : 8/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Matinas BioPharma Holdings might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Matinas BioPharma Holdings  (AMEX:MTNB) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Matinas BioPharma Holdings GF Score Related Terms

MTNB vs SXTP, ARTL, GLMD: GF Score Comparison

For the Biotechnology subindustry, Matinas BioPharma Holdings's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Matinas BioPharma Holdings GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's GF Score distribution charts can be found below:

* The bar in red indicates where Matinas BioPharma Holdings's GF Score falls into.


MTNB
31GF Score
Matinas BioPharma Holdings Inc MTNB
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 31 mean?
Matinas BioPharma Holdings (MTNB) has a GF Score of 31 as of Jul. 03, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Matinas BioPharma Holdings and its competitors. This is 14% below median its historical median of 36.00. Over the past decade, Matinas BioPharma Holdings' GF Score has ranged from 16.00 to 57.00.
Is Matinas BioPharma Holdings' GF Score too high?
Matinas BioPharma Holdings' current GF Score of 31 is 14% below median its 10-year median of 36.00. Over the past 10 years, this metric has ranged from a low of 16.00 to a high of 57.00. Overall, Matinas BioPharma Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Matinas BioPharma Holdings' GF Score compare to SXTP and ARTL?
Matinas BioPharma Holdings' GF Score of 31 can be compared against companies in the Biotechnology industry. Historically, Matinas BioPharma Holdings' own GF Score has ranged from 16.00 to 57.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Matinas BioPharma Holdings and its competitors. Matinas BioPharma Holdings's current GF Score is 31, which is 14% below median its own 10-year median of 36.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Matinas BioPharma Holdings stock overvalued right now?
Matinas BioPharma Holdings (MTNB) has a current GF Score of 31. The current GF Score is 31, which is 14% below median its 10-year median of 36.00. Matinas BioPharma Holdings' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Matinas BioPharma Holdings (MTNB), the current GF Score is 31 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Matinas BioPharma Holdings Business Description

Address 1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
31GF Score

Get the complete analysis for MTNB

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.63
Price